Your left hand and your right hand are mirror images of each other, where no matter how you rotate or flip one hand, it will never perfectly overlap the other. This property is called chirality, from the Greek word for hand, and it is one of the most consequential phenomena in all of pharmaceutical chemistry. Many molecules are chiral and getting chirality wrong can be the difference between a cure and a catastrophe.
The Chemistry of Chirality
A molecule is chiral when it contains a chiral centre which is a carbon atom bonded to four different substituents, arranged tetrahedrally. Because the four groups are all different, they can be arranged in two distinct spatial configurations that are non-superimposable mirror images of each other called enantiomers.
Enantiomers share identical physical properties (the same melting point, boiling point, and solubility). The one property that distinguishes them is their interaction with plane-polarised light as one enantiomer rotates the plane of polarisation clockwise and is described as dextrorotatory (+), while the other rotates it anticlockwise and is described as laevorotatory (−). This property called optical activity, is detected using a polarimeter and is the experimental basis for characterising enantiomers.
A racemic mixture, also called a racemate, contains equal amounts of both enantiomers. Because their optical rotations are equal and opposite, they cancel out, and the racemic mixture shows zero net optical rotation. In the laboratory, when a chiral molecule is synthesised from achiral starting materials without a chiral catalyst or chiral reagent, a racemic mixture is almost always produced meaning that both enantiomers form in equal amounts because there is no asymmetric influence to favour one configuration over the other, which is where the pharmaceutical problem begins.
Chirality in Biology
Living systems are constructed from chiral molecules. For example, the amino acids that make up proteins are almost exclusively L-enantiomers, and the sugars in DNA and RNA are exclusively D-enantiomers. That means every receptor, enzyme, and binding site in your body has a defined three-dimensional chirality. When a drug molecule arrives at its target, it is fitting into a chiral environment that has a strong preference for one enantiomer over the other.
A drug molecule interacts with its biological target through intermolecular forces such as hydrogen bonds, van der Waals forces, and electrostatic interactions that depend critically on the precise three-dimensional complementarity between the drug and the binding site. If a drug molecule is chiral, its two enantiomers will interact with a chiral biological target very differently. One enantiomer may bind with high affinity and produce the desired therapeutic effect. The other may bind poorly, fail to bind at all, or most dangerously bind to an entirely different biological target and produce entirely different, potentially harmful effects.
The Thalidomide Disaster
Developed in the late 1950s, thalidomide was prescribed as a sedative and as a treatment for morning sickness in pregnant women. It was administered as a racemic mixture of its two enantiomers. The (R)-enantiomer produces the desired sedative effect, binding to its intended target and functioning as expected. The (S)-enantiomer is teratogenic, meaning that it interferes with the development of blood vessels in the embryo by binding to a protein called cereblon, inhibiting the expression of genes essential for limb development.
Between 1957 and 1962, approximately 10,000 children were born with severe limb malformations in countries where thalidomide was prescribed to pregnant women, making it one of the worst pharmaceutical disasters in history.
Furthermore, even if pure (R)-thalidomide had been administered, it would not have been safe. Thalidomide undergoes chiral inversion under physiological conditions as the R enantiomer spontaneously interconverts with the S enantiomer in the body, meaning that separating the enantiomers before administration would not have prevented the tragedy. This illustrates an important principle that understanding chirality in drug development requires understanding the full metabolic pathway of each enantiomeric form in the body, not merely its initial configuration.
The thalidomide disaster drove a global tightening of drug approval processes. In the United States, it strengthened the FDA's requirement for rigorous proof of both safety and efficacy before market approval, a regulatory framework that shapes pharmaceutical development to this day.
The Rise of Enantiopure Drugs
In the aftermath of thalidomide and the deepening understanding of stereochemistry, the pharmaceutical industry began shifting decisively toward enantiopure drugs - medicines containing only a single enantiomer rather than a racemic mixture. The process of reformulating an existing racemic drug as a pure enantiomer is called chiral switching, and it has produced some of the most commercially and clinically significant drugs in modern medicine.
Ibuprofen is sold as a racemate, but only the (S)-enantiomer is pharmacologically active as the S form inhibits COX enzymes and reduces prostaglandin synthesis, producing the anti-inflammatory and analgesic effects. The R enantiomer is pharmacologically inactive, though it is slowly converted to the S form metabolically. Enantiopure S-ibuprofen reaches therapeutic concentrations faster and at lower doses.
Omeprazole, sold as Losec, is a racemic proton pump inhibitor that reduces gastric acid secretion. When the omeprazole patent was approaching expiry, AstraZeneca developed esomeprazole (Nexium), the pure S enantiomer, arguing it had improved efficacy and a more favourable pharmacokinetic profile. Critics characterised this as evergreening: using chiral switching to extend effective patent protection and revenue streams rather than deliver genuine therapeutic innovation.
Salbutamol, the active ingredient in Ventolin inhalers, is a racemate. The (R)-enantiomer produces the bronchodilation that makes it effective in asthma treatment, acting on β₂-adrenergic receptors in airway smooth muscle. The (S)-enantiomer may actually produce mild bronchoconstriction, the opposite of the desired effect. Levalbuterol, the pure R enantiomer, was developed to deliver the therapeutic benefit without the potentially counterproductive contribution of the S form.
How Chemists Produce Enantiopure Compounds
Producing a single enantiomer rather than a racemic mixture requires deliberate chemical strategy. Two main approaches are used in pharmaceutical synthesis, as described below.
The first is resolution, the synthesis of a racemic mixture and then separating the enantiomers. One method involves reacting the racemate with a chiral resolving agent (a pure enantiomer of another compound) to produce diastereomers. Unlike enantiomers, diastereomers are not mirror images of each other and therefore have different physical properties, including different melting points and different solubilities, allowing them to be separated by conventional techniques such as fractional crystallisation. Once separated, the resolving agent is removed to recover the desired pure enantiomer.
The second approach is asymmetric synthesis, designing reactions that produce one enantiomer preferentially from the outset, using chiral catalysts or chiral reagents that impose asymmetry on the reaction mechanism. The 2001 Nobel Prize in Chemistry was awarded to William Knowles, Ryoji Noyori, and Karl Barry Sharpless for their development of asymmetric catalysis, a direct acknowledgement of how central enantioselective synthesis had become to pharmaceutical chemistry. Increasingly, biocatalysis using enzymes, which are themselves chiral, to perform stereospecific transformations is also employed in industrial pharmaceutical synthesis, offering selectivity under mild conditions.